Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Eli Lilly said Monday it would acquire an experimental cancer program from startup Scorpion Therapeutics in a deal worth up ...

In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a ...

Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...

In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a strategic ...